Sutent
FDA Expands Sutent Approval to Include Post-Nephrectomy Adjuvant Rx
The FDA approved adjuvant treatment with sunitinib (Sutent, Pfizer) for adults at high risk for a recurrence of ...
NOVEMBER 17, 2017
Alternate Sunitinib Schedule Is Feasible for mRCC
Although an alternate schedule of sunitinib in patients with mRCC failed to reduce grade 3 or higher toxicity ...
JULY 18, 2017
Individualized Sunitinib Dosing Provides Better Fit
Customized dosing of first-line sunitinib is safe and feasible, providing better response rates and survival in ...
JUNE 27, 2017
Adjuvant Sorafenib, Sunitinib Don’t Prevent RCC Recurrence
In resected local kidney cancer at high risk for recurrence, sorafenib or sunitinib did not increase survival
MAY 24, 2016
Load more